Job title: Vice President, Global Medical Affairs
Eileen Sawyer joined uniQure in 2016, where she serves as Vice President and Head of Medical Affairs, leading uniQure’s medical affairs activities across the portfolio with a focus on supporting the hemophilia B gene therapy program. Prior to joining uniQure, she spent 3 years at Alexion Pharmaceuticals where she served as the scientific communications lead for the launch of asfotase alfa (Strensiq), an enzyme replacement for a rare metabolic disease. Eileen earned her PhD in Neuroscience from Emory University in 2011 and conducted her post-doctoral training in preclinical drug discovery at Harvard University prior to transitioning to industry.
Panel Discussion – Assessing the Commercial Realities of Launching Gene Therapies in the Blood Disorder Space 9:15 am
Determining the most effective ways of demonstrating product value Ensuring accessibility of products through co-operation with payers and patients Discussing creative solutions to increase accessibility to patients by overcoming cost and geographic barriersRead more
day: Day One